Sen-Jam Pharmaceutical

About the offering

Why Sen-Jam? Targeting inflammation at its root. Preserving vitality. Unlocking massive value. Sen-Jam is reshaping the future of inflammatory care—delivering a platform-level solution to prevent disease and transform a trillion-dollar economy. It’s the right science, the right moment, and the right team to make it real - and the kind of opportunity that builds generational wealth for those bold enough to believe early. Sen-Jam Pharmaceutical is at the forefront of a healthcare revolution, addressing the pervasive impacts of chronic inflammation and metabolic disorders, including obesity and related conditions. Our proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) Technology offers a groundbreaking approach that works with the body’s innate wisdom to modulate inflammation and metabolic dysfunction at their source. By reducing systemic risks without suppressing the immune system, we deliver transformative solutions that enhance vitality, extend health spans, and redefine how the world heals. At Sen-Jam, we saw long ago what most of the pharma industry missed: Inflammation isn’t a consequence of disease—it’s the cause. And now, with inflammatory care rising to pharma’s #2 global priority (just behind oncology), the world is finally catching up. This isn’t just innovation—it’s a redefinition of what medicine should be. While others have focused on chasing symptoms with costly, late-stage interventions, we’ve focused on restoring balance before dysfunction takes hold. PAIR Technology was born from a radical yet elegant idea: that by calming inflammation early, we could stop disease before it starts. Built to Deliver Returns. Designed to Reward Early Believers. We’re not just building the next generation of inflammation therapeutics—we’re building a platform designed to deliver real impact and real returns. For those who join us now, we’re offering exclusive, performance-aligned incentives as we enter the next phase of this transformational raise. As we launch Tranche IV of our Fractional Royalty Rights (FRR) incentive we are offering: 1% of the SJP-001 Patent Portfolio, shared pro-rata across the first $1M invested in this round—starting at just $1K. With a 60+ global patent portfolio, 11 pipeline assets, and two lead programs—SJP-001 (alcohol and food overindulgence - metabolic recovery) entering Phase 2 and SJP-002C (respiratory infection) already completing Phase 2—the opportunity is well-positioned and moving fast. This is a moment to back science with momentum—and get rewarded for believing early. This is a phenomenal chance to make history together, as we change the course of inflammation, for good. We believe this is a rare inflection point in both medicine and markets—a chance to lead a seismic shift in how the world treats inflammation, and in doing so, extend healthspan for millions. We’ve built the platform, secured the science, and now we’re inviting investors to join us as we scale. Here’s a clear look at what we’ve built, how we’re doing it, and why the timing—and opportunity—is so compelling. Think of this like backing a breakthrough before the world catches on—and this one’s focused on transforming how we handle pain and inflammation. Sen-Jam is a next-gen pharma platform aiming to reshape how the world treats inflammation—and how the pharmaceutical industry treats people. We want to be an end to pharma as perpetuating sick care and ignite an era of healthspan extension and vitality preservation. Born from the insight of a visionary pharmacist and research fellow at Memorial Sloan Kettering, our approach combines two overlooked, FDA-approved molecules into what may be the most significant advancement in anti-inflammatories since aspirin. With a multi-patented platform, a de-risked regulatory path, and products advancing to Phase 2, we’re moving at speed to bring safe, scalable, and proprietary inflammation therapeutics to market faster than ever before. But to bring our vision to life, we had to confront a hard truth: the system we rely on to keep us healthy was never built to prevent illness in the first place. The Truth? Unchecked inflammation silently erodes health, fueling a system built on sick care. Revolutionizing inflammatory care flips the script to preservation - shifting from treatment to preservation, from reacting to preventing. Because... For too long, modern medicine has waited for symptoms to strike before it responds. The entire system is reactive—designed to manage crises, not prevent them. Inflammation quietly builds in the background, feeding disease after disease, while pharma plays catch-up downstream. We believe this reactive approach is failing billions. What’s needed is a shift—a proactive, upstream intervention that targets the root cause before damage begins. The Inflammation Epidemic Is Massive - Costing Lives and Trillions of Dollars Inflammation is no longer niche. It’s now: The #2 pharma category globally, second only to cancer, The hidden culprit behind 50% of global deaths, A $10T+ economic burden, spanning obesity, addiction, COVID, arthritis, sepsis, and more. Yet current anti-inflammatories only manage symptoms—too late, too weak, too toxic. PAIR is different. We prevent progression. We protect vitality. We scale fast. Sen-Jam is built on the revolutionary insight of Sen-Jam co-founder and visionary pharmacist, Jackie Iverson RPh MS. After working relentlessly at Memorial Sloan Kettering Cancer Center as a Pain Management Research Fellow, Jackie realized:: Why are we treating inflammation so late, when we have the means to prevent it in the first place? And from this powerful insight, the SJP platform was born. “I saw what others didn’t: that two proven, long established molecules—combined precisely—could unlock a new frontier in medicine. It’s elegant pharmacology built to reset the body before disease begins.” — Jackie Iversen, RPh, MS, Co-founder & Inventor Our drugs calm the overactive inflammatory response of an individual’s innate immune system, providing broad full body anti-Inflammatory action before it damages tissue, harms organs or spreads into full-on disease. Where others arrive late, we intervene early. Where others suppress, we rebalance. Real Science. Real Results. Ready to Scale. Jackie’s insight didn’t just spark a new approach—it launched a platform now backed by both science and strategy. We’ve published 13 peer-reviewed studies validating our approach in everything from opioid withdrawal and vaccine side-effect reduction to upper respiratory infections and metabolic recovery. Across every test, the emerging data tells the same story: PAIR works. And it works without suppressing the immune system. This isn’t theoretical. It’s clinically grounded. It’s commercially de-risked. Our model doesn’t rely on selling pills—it’s built for platform licensing at scale. That means upfront payments, milestones, and royalties from pharma and consumer health partners who want to tap into our IP-protected pipeline. And because our therapeutics repurpose FDA-approved molecules, we leverage the 505(b)(2) fast track to reduce risk, shorten time to market, and accelerate revenue generation. With FDA-grade manufacturing already secured via our partner KVK-Tech and IP protections in 23+ countries, we’re not just building a better approach to inflammation—we’re making it globally viable, fast. Our Pipeline: Broad, De-risked, and Ready to Move We’re advancing 11 assets across 8 disease categories, including: SJP-001: For alcohol and food overindulgence (Hangover, Metabolic Recovery) → Phase 2 SJP-002C: For respiratory infections (COVID, RSV, colds) → Phase 2 complete SJP-005: For opioid withdrawal → IND-ready SJP-100: For hospital rescue, arthritis, aging → Preclinical SJP-002: For common cold infections - an area in much need of innovation These programs are supported by Duke University, NIDA, People Science, and KVK-Tech. Sen-Jam is rewriting the story of inflammatory care—powered by a world-class team on a mission to transform lives. Our Edge: Experience, Exit History, and Purpose -$730M+ in exits by our leadership team -Deep pharma experience from Sloan Kettering, Harvard, Mayo, MIT -Advisors from Cornell, Boston Medical, and more -Clinical insight from bedside to boardroom -And yes—we call ourselves the Good Karma Pharma People Because for us, changing the way we treat inflammation means changing the way pharma treats humanity. Built for Returns. Backed by Science. Ready for Scale. At Sen-Jam, we aren’t just rewriting how the world treats inflammation—we’re redefining what investors should expect from breakthrough biotech disrupting a multi-trillion dollar healthcare economy. We’ve de-risked our path by repurposing FDA-approved molecules, accelerated timelines via 505(b)(2), and secured over 60 global patents across a 11-asset platform. Our Phase 2-ready programs in metabolic recovery, respiratory illness, and opioid withdrawal are positioned to unlock licensing opportunities and non-dilutive revenues. We’re not chasing a drug. We’ve built a platform. This raise doesn’t just move us forward—it catapults us beyond the status quo: For those who join us now, we’re offering exclusive perks to reward early conviction. Because when you help lead a health revolution, you should share in the upside. We are raising capital to execute Phase 2 clinical trials for our three lead assets, as well as to prove to our potential partners and institutional investors that our platform is something consumers want. Sen-Jam is creating a new category in the $1.48T pharmaceutical industry by focusing on preventing disease caused by inflammation, instead of treatment. The current global market for anti-inflammatory drugs, valued at $111B and growing at a CAGR of 9.3%, only includes solutions that treat symptoms. We estimate we can capture a larger $367B opportunity across the myriad of conditions that have inflammation as the root cause. Join Us in Redefining What It Means to Heal If you believe, as we do, that the future of medicine lies in prevention—not reaction—then now is your moment. Sen-Jam is leading a transformation in how the world understands and treats inflammation, one that doesn't just delay disease but prevents it, preserves vitality, and restores the body’s natural balance. By modulating inflammation at the source, we’re not only reshaping the pharmaceutical model—we’re rewriting the human healthspan. Imagine what a few more healthy, vibrant years could mean for you. For someone you love. For billions worldwide. We’re not just building a platform—we’re building a future where medicine empowers people, not just manages pain. This is the inflection point. And we’re inviting you to be part of it. Watch our video. Learn the vision. Invest today—and help us change what’s possible.

FAQ